| abstract |
In the present invention, a novel Aggrus domain involved in binding to CLEC-2 was explored, and a monoclonal antibody recognizing the domain was obtained. The newly discovered PLAG4 domain is important in binding to CLEC-2, and a monoclonal antibody recognizing this region was developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, and cancer metastasis inhibitors using the antibody. |